- Home
- CLRO vs MEIP Comparison
CLRO vs MEIP Comparison
Compare CLRO & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRO
- MEIP
- Stock Information
- Founded
- CLRO 1983
- MEIP 2000
- Country
- CLRO United States
- MEIP United States
- Employees
- CLRO N/A
- MEIP N/A
- Industry
- CLRO Radio And Television Broadcasting And Communications Equipment
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- CLRO Technology
- MEIP Health Care
- Exchange
- CLRO Nasdaq
- MEIP Nasdaq
- Market Cap
- CLRO N/A
- MEIP 17.1M
- IPO Year
- CLRO N/A
- MEIP 2003
- Fundamental
- Price
- CLRO $0.59
- MEIP $2.19
- Analyst Decision
- CLRO
- MEIP Hold
- Analyst Count
- CLRO 0
- MEIP 2
- Target Price
- CLRO N/A
- MEIP $7.00
- AVG Volume (30 Days)
- CLRO 200.1K
- MEIP 8.6K
- Earning Date
- CLRO 05-19-2025
- MEIP 05-08-2025
- Dividend Yield
- CLRO 81.83%
- MEIP N/A
- EPS Growth
- CLRO N/A
- MEIP N/A
- EPS
- CLRO N/A
- MEIP N/A
- Revenue
- CLRO $11,386,000.00
- MEIP N/A
- Revenue This Year
- CLRO N/A
- MEIP N/A
- Revenue Next Year
- CLRO N/A
- MEIP N/A
- P/E Ratio
- CLRO N/A
- MEIP N/A
- Revenue Growth
- CLRO N/A
- MEIP 33.76
- 52 Week Low
- CLRO $0.45
- MEIP $2.19
- 52 Week High
- CLRO $1.88
- MEIP $4.11
- Technical
- Relative Strength Index (RSI)
- CLRO 47.43
- MEIP 29.74
- Support Level
- CLRO $0.60
- MEIP $2.28
- Resistance Level
- CLRO $0.68
- MEIP $2.35
- Average True Range (ATR)
- CLRO 0.06
- MEIP 0.07
- MACD
- CLRO -0.01
- MEIP 0.00
- Stochastic Oscillator
- CLRO 19.55
- MEIP 0.00
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.